Search Results - "Peluso, Teresa"

Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma by Dimopoulos, Meletios A., Palumbo, Antonio, Corradini, Paolo, Cavo, Michele, Delforge, Michel, Di Raimondo, Francesco, Weisel, Katja C., Oriol, Albert, Hansson, Markus, Vacca, Angelo, Blanchard, María Jesús, Goldschmidt, Hartmut, Doyen, Chantal, Kaiser, Martin, Petrini, Mario, Anttila, Pekka, Cafro, Anna Maria, Raymakers, Reinier, San-Miguel, Jesus, de Arriba, Felipe, Knop, Stefan, Röllig, Christoph, Ocio, Enrique M., Morgan, Gareth, Miller, Neil, Simcock, Mathew, Peluso, Teresa, Herring, Jennifer, Sternas, Lars, Zaki, Mohamed H., Moreau, Philippe

“…Patients with relapsed and/or refractory multiple myeloma (RRMM) have poor prognosis. The STRATUS study assessed safety and efficacy of pomalidomide plus…”
Get full text

Ovarian Aging: Role of Pituitary-Ovarian Axis Hormones and ncRNAs in Regulating Ovarian Mitochondrial Activity by Colella, Marco, Cuomo, Danila, Peluso, Teresa, Falanga, Ilaria, Mallardo, Massimo, De Felice, Mario, Ambrosino, Concetta

“…The number of mitochondria in the oocyte along with their functions (e.g., energy production, scavenger activity) decline with age progression. Such…”
Get full text

Chronic Exposure to Chlorpyrifos Damages Thyroid Activity and Imbalances Hepatic Thyroid Hormones Signaling and Glucose Metabolism: Dependency of T3-FOXO1 Axis by Hyperglycemia by Peluso, Teresa, Nittoli, Valeria, Reale, Carla, Porreca, Immacolata, Russo, Filomena, Roberto, Luca, Giacco, Antonia, Silvestri, Elena, Mallardo, Massimo, De Felice, Mario, Ambrosino, Concetta

“…Early life exposure to Endocrine Disruptor Chemicals (EDCs), such as the organophosphate pesticide Chlorpyrifos (CPF), affects the thyroid activity and…”
Get full text

Pomalidomide‐bortezomib‐dexamethasone in relapsed or refractory multiple myeloma: Japanese subset analysis of OPTIMISMM by Sunami, Kazutaka, Matsue, Kosei, Suzuki, Kenshi, Takezako, Naoki, Shinagawa, Atsushi, Sakurai, Sanae, Tamakoshi, Hiromi, Biyukov, Tsvetan, Peluso, Teresa, Richardson, Paul

“…In the phase 3 OPTIMISMM trial, pomalidomide, bortezomib and dexamethasone (PVd) significantly improved the progression‐free survival (PFS) and the overall…”
Get full text

Immunomodulation of NK, NKT and B/T cell subtypes in relapsed/refractory multiple myeloma patients treated with pomalidomide along with velcade and dexamethasone and its association with improved progression-free survival by Prabhala, Rao, Pierceall, William E, Samur, Mehmet, Potluri, Lakshmi B, Hong, Kevin, Peluso, Teresa, Talluri, Srikanth, Wang, Angela, Katiki, Aishwarya, Vangala, Sahan D, Buonopane, Michael, Bade, Vaishnavi, Seah, Hannah, Krogman, Arthur, Derebail, Sanika, Fulciniti, Mariateresa, Lazo, Suzan B, Richardson, Paul, Anderson, Kenneth, Corre, Jill, Avet-Loiseau, Herve, Thakurta, Anjan, Munshi, Nikhil

“…Multiple Myeloma (MM) patients exhibit dysregulated immune system, which is further weakened by chemotherapeutic agents. While cereblon-modulating agents, such…”
Get full text

New Chemical Systems for the Removal of Calcareous Encrustations on Monumental Fountains: A Case Study of the Nymphaeum of Cerriglio by Squarciafico, Claudia, Salatino, Giorgia, La Russa, Mauro Francesco, Peluso, Teresa, Basile, Lorenzo, Barbagallo, Fina Serena, Coppola, Monica, Macchia, Andrea

“…This study aims to compare the effects of some chemical agents on the removal of calcareous encrustations, which are characterized by the presence of both…”
Get full text

Aiding early clinical drug development by elucidation of the relationship between tumor growth inhibition and survival in relapsed/refractory multiple myeloma patients by Cheng, Yiming, Hong, Kevin, Chen, Nianhang, Yu, Xin, Peluso, Teresa, Zhou, Simon, Li, Yan

“…Early prognosis of clinical efficacy is an urgent need for oncology drug development. Herein, we systemically examined the quantitative approach of tumor…”
Get full text

P868: MEZIGDOMIDE (MEZI) PLUS DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM THE DOSE‐EXPANSION PHASE OF THE CC‐92480‐MM‐001 TRIAL by Bahlis, Nizar J, Trudel, Suzanne, Quach, Hang, Popat, Rakesh, Lonial, Sagar, Orlowski, Robert Z, Kim, Kihyun, Mateos, Maria‐Victoria, Pawlyn, Charlotte, Ramasamy, Karthik, Martinez‐Lopez, Joaquín, Casas‐Avilés, Ignacio, Spirli, Alessia, Gong, Jing, Amatangelo, Michael, Katz, Jessica, Maciag, Paulo, Peluso, Teresa, Richardson, Paul

Get full text

Sample-Pooling Strategy for SARS-CoV-2 Detection among Students and Staff of the University of Sannio by Polvere, Immacolata, Silvestri, Elena, Sabatino, Lina, Giacco, Antonia, Iervolino, Stefania, Peluso, Teresa, Guida, Rosa, Zerillo, Lucrezia, Varricchio, Romualdo, D’Andrea, Silvia, Voccola, Serena, Madera, Jessica Raffaella, Zullo, Alberto, Stilo, Romania, Vito, Pasquale, Zotti, Tiziana

“…Since the beginning of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic, it has been clear that testing large groups of the population…”
Get full text

Model‐based analysis for the population pharmacokinetics of iberdomide and its major active metabolite in healthy subjects and patients with relapsed and refractory multiple myeloma by Cheng, Yiming, Xue, Yongjun, Chen, Lu, Masin, Mark, Maciag, Paulo, Peluso, Teresa, Zhou, Simon, Li, Yan

“…Aims A parent‐metabolite population pharmacokinetic (popPK) model of iberdomide and its pharmacologically active metabolite (M12) was developed and the…”
Get full text

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial by Richardson, Paul G, Beksac, Meral, Liberati, Anna Marina, Galli, Monica, Lindsay, Jindriska, White, Darrell, Facon, Thierry, San Miguel, Jesus, Sunami, Kazutaka, O'Gorman, Peter, Sonneveld, Pieter, Robak, Pawel, Schey, Steve, Yu, Xin, Bensmaine, Amine, Zaki, Mohamed, Abildgaard, Niels, Adler, Howard, Altuntas, Fevzi, Arce-Lara, Carlos, Aydin, Yildiz, Basu, Supratik, Battini, Ramakrishna, Beeker, Thaddeus, Ben-Yehuda, Dina, Boccia, Ralph, Cavo, Michele, Chantry, Andrew, Chaudhry, Arvind, Corso, Alessandro, De Arriba, Felipe, Delimpasi, Sosana, Desjardins, Pierre, Dhakal, Binod, Di Bartolomeo, Paolo, Dürig, Jan, Engelhardt, Monika, Esteves, Graca, Flogegard, Max, Gabrail, Nashat, Gamberi, Barbara, Garrison, Mitchell, Gisslinger, Heinz, Goldschmidt, Hartmut, Gressot, Laurent, Grosicki, Sebastian, Hanna, Wahid, Henriques Bernardo, Maria Manuela, Hermann, Robert, Holden, Viran, Huben, Marianne, Janakiram, Murali, Jenner, Matthew, João, Cristina, Jurcyszyn, Artur, Kalayoğlu Beşişik, Sevgi, Kambhampati, Suman, Karadoğan, Ihsan, Khojasteh, Ali, Kirkel, Dean, Komarnicki, Mieczyslaw, Lauri, Birgitta, Leleu, Xavier, Matsue, Kosei, Mendeleeva, Larisa, Miller, Carole, Mohrbacher, Ann, Müldür, Ercan, Naassan, Anthony, Nahi, Hareth, Nair, Rajesh, O'Dwyer, Mike, Openshaw, Thomas, O'Rourke, Timothy, Osswald, Michael, Overton, Lindsay, Pavic, Michel, Pierola, Ana Alfonso, Rabin, Neil, Ramasamy, Karthik, Rambaldi, Alessandro, Rodriguez, Paula, Röllig, Christoph, Rosenblatt, Jacalyn, Rosenbluth, Jonathan, Salomo, Morten, Samoylova, Olga, Sastre Moral, Jose, Shafeek, Salim, Shinagawa, Atsushi, Sleckman, Bethany, Smith, Clay, Suzuki, Kenshi, Takezako, Naoki, Teke, Hava Üsküdar, Vapaatalo, Mirja, Vassilopoulos, George, Verma, Amit, Wang, Xiang Sean, Yağci, Munci

“…As lenalidomide becomes increasingly established for upfront treatment of multiple myeloma, patients refractory to this drug represent a population with an…”
Get full text

Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse by Dimopoulos, Meletios, Weisel, Katja, Moreau, Philippe, Anderson, Larry D., White, Darrell, San-Miguel, Jesus, Sonneveld, Pieter, Engelhardt, Monika, Jenner, Matthew, Corso, Alessandro, Dürig, Jan, Pavic, Michel, Salomo, Morten, Casal, Eva, Srinivasan, Shankar, Yu, Xin, Nguyen, Tuong Vi, Biyukov, Tsvetan, Peluso, Teresa, Richardson, Paul

“…In the phase 3 OPTIMISMM trial, pomalidomide, bortezomib, and dexamethasone (PVd) demonstrated superior efficacy vs bortezomib and dexamethasone (Vd) in…”
Get full text

Pax8 and Nkx2-1 haploinsufficiencies differentially affect liver metabolic pathways by Giacco, Antonia, Peluso, Teresa, Cioffi, Federica, Iervolino, Stefania, Mercurio, Giovanna, Roberto, Luca, Reale, Carla, Colella, Marco, De Felice, Mario, Moreno, Maria, Ambrosino, Concetta, Silvestri, Elena

“…Thyroid dysfunctions are associated with liver diseases ranging, in severity, from insulin resistance (IR) to hepatocellular carcinoma. The pathogenic…”
Get full text

Brain Abnormalities in Young Single- and Double-Heterozygote Mice for Both Nkx2-1- and Pax8-Null Mutations by Giacco, Antonia, Iervolino, Stefania, Cioffi, Federica, Peluso, Teresa, Mercurio, Giovanna, Roberto, Luca, de Rosa, Valeria, Cammarota, Mariarosaria, Varricchio, Silvia, Staibano, Stefania, Boscia, Francesca, Canzoniero, Lorella Maria Teresa, De Felice, Mario, Ambrosino, Concetta, Moreno, Maria, Silvestri, Elena

“…In humans and mice, Nkx2-1 and Pax8 are crucial morphogenic transcription factors defining the early development of the thyroid and specific extrathyroidal…”
Get full text

Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma by Richardson, Paul G., Trudel, Suzanne, Popat, Rakesh, Mateos, María-Victoria, Vangsted, Annette J., Ramasamy, Karthik, Martinez-Lopez, Joaquín, Quach, Hang, Orlowski, Robert Z., Arnao, Mario, Lonial, Sagar, Karanes, Chatchada, Pawlyn, Charlotte, Kim, Kihyun, Oriol, Albert, Berdeja, Jesus G., Rodríguez Otero, Paula, Casas-Avilés, Ignacio, Spirli, Alessia, Poon, Jennifer, Li, Shaoyi, Gong, Jing, Wong, Lilly, Lamba, Manisha, Pierce, Daniel W., Amatangelo, Michael, Peluso, Teresa, Maciag, Paulo, Katz, Jessica, Pourdehnad, Michael, Bahlis, Nizar J.

“…Oral mezigdomide is a cereblon-modifying agent that results in degradation of transcription factors essential for myeloma cell survival. Given with…”
Get full text

OA-44 Pomalidomide, bortezomib, and dexamethasone vs bortezomib and dexamethasone in relapsed or refractory multiple myeloma (OPTIMISMM): final survival outcomes from a randomized, open-label, phase 3 trial by Beksac, Meral, Richardson, Paul, Oriol, Albert, Lindsay, Jindriska, Schjesvold, Fredrik, Galli, Monica, Yağci, Münci, Larocca, Alessandra, Weisel, Katja, Yu, Xin, Donahue, Cynthia, Acosta, Jorge, Peluso, Teresa, Dimopoulos, Meletios

Get full text

Mezigdomide (CC-92480), a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD), Combined with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Dose-Expansion Phase of the CC-92480-MM-001 Trial by Richardson, Paul G., Trudel, Suzanne, Quach, Hang, Popat, Rakesh, Lonial, Sagar, Orlowski, Robert Z., Kim, Kihyun, Mateos, María-Victoria, Pawlyn, Charlotte, Ramasamy, Karthik, Martinez-Lopez, Joaquín, Spirli, Alessia, Casas-Avilés, Ignacio, Gong, Jing, Amatangelo, Michael, Katz, Jessica, Maciag, Paulo, Peluso, Teresa, Bahlis, Nizar J.

Get full text

Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Dose-Expansion Phase of the CC-220-MM-001 Trial by Lonial, Sagar, Popat, Rakesh, Hulin, Cyrille, Jagannath, Sundar, Oriol, Albert, Richardson, Paul G., Facon, Thierry, Weisel, Katja, Larsen, Jeremy T., Minnema, Monique C., Abdallah, Al-Ola, Badros, Ashraf Z., Knop, Stefan, Stadtmauer, Edward A., Chen, Min, Nguyen, Tuong Vi, Amin, Alpesh, Kueenburg, Elisabeth, Peluso, Teresa, van de Donk, Niels W.C.J.

“…Introduction: Despite recent advances, MM remains incurable and new therapeutic options are needed, particularly for pts with RRMM. IBER is a novel, potent…”
Get full text

CC-92480, a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, in Combination with Dexamethasone (DEX) and Bortezomib (BORT) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Phase 1/2 Study CC-92480-MM-002 by Richardson, Paul G., Ocio, Enrique, Raje, Noopur S., Gregory, Tara, White, Darrell, Oriol, Albert, Sandhu, Irwindeep, Raab, Marc-Steffen, LeBlanc, Richard, Rodriguez, Cesar, Trudel, Suzanne, Wäsch, Ralph, Perrot, Aurore, Bahlis, Nizar J., Zhou, Zehua, Lamba, Manisha, Amatangelo, Michael, Civardi, Tiziana, Katz, Jessica, Maciag, Paulo, Peluso, Teresa, Dimopoulos, Meletios A.

“…Introduction: CC-92480 is a potent, novel CELMoD ® compound designed for rapid and maximal degradation of Ikaros and Aiolos, that has shown immunostimulatory…”
Get full text

P-231: Biomarker analysis to support dose optimization of iberdomide (IBER) as monotherapy and in combination with standard of care treatments for multiple myeloma from a phase 1/2 trial by Amatangelo, Michael, Cheng, Yiming, Pierceall, William, van de Donk, Niels W.C.J., Lonial, Sagar, Wang, Maria, Emerson, Joshua, Hong, Kevin, Maciag, Paulo, Peluso, Teresa, Gandhi, Anita, Thakurta, Anjan

Get full text